CELL INTELLIGENCE · 肿瘤细胞治疗研究

CD7 CAR-T 治疗：当前进展、改进与困境

CD7 CAR-T therapy: current developments, improvements, and dilemmas.

非基因编辑 CD7 CAR-T 细胞治疗 CD7(+) Sézary 综合征的病例报告：临床前验证与首次人体应用

Case report of non-gene editing CD7 CAR T cell therapy in CD7(+) Sézary syndrome: preclinical validation and first-in-human use.

我们的 CD7-RTX CAR-T 疗法在 1 例 CD7⁺ r/r SS 患者中展现出卓越的安全性和疗效。

SOHO 最新进展与下一步问题 | CD7 CAR-T 治疗 CD7 阳性血液系统恶性肿瘤：临床进展与未来方向

SOHO State of the Art Updates and Next Questions | CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies: Clinical Advances and Futur

靶向 CD7 的 CAR-T 细胞治疗 T 淋巴细胞白血病和淋巴瘤与急性髓系白血病：近期进展

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.

趋化因子受体 CCR8 是治疗 T 细胞恶性肿瘤的嵌合抗原 T 细胞靶点

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies.

基于嵌合抗原受体的细胞疗法治疗 T 细胞恶性肿瘤

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.

表达含全人源仅重链结构域 CD5/CD7 双特异性嵌合抗原受体的 T 细胞可减轻肿瘤抗原逃逸

T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.